A Study for Patients With Pancreatic Cancer

Phase 1 will be a dose escalation of doses 70 mg/m2 to 300 mg/m2 divided into 6 cohorts.
Each patient will be assigned to a single cohort with no intrapatient dose escalation.
Patients will received gemcitabine on days 1, 8, and 15 followed by LY2603618 on days 2, 9,
and 16 of each 28 day cycle. The phase 1 portion will enroll approximately 26 patients
total to determine the maximum tolerated dose to be carried into the phase 2 portion of the
study.

Inclusion Criteria:

- Diagnosed with cancer that is metastatic and/or advanced during Phase 1

- Diagnosed with pancreatic cancer that is metastatic and not amenable to surgery

- Must be 18 years of age

- Adequate hematological, liver, and renal functions

- ECOG status 0-2

Exclusion Criteria:

- Known hypersensitivity to gemcitabine

- Pregnant or lactating females or refusal to use medically approved contraceptive
precautions

- Had prior treatment with radiotherapy involving more than 25% of marrow producing
area

- Have received treatment in the last 30 days with a drug which has not received
regulatory approval for any indication at the time of study entry